News | Implantable Cardioverter Defibrillator (ICD) | November 04, 2015

LivaNova Launches Platinum ICD/CRT-D Family

Released simultaneously in both Europe and Japan, devices will protect patients from avoidable replacement surgeries

LivaNova, Platinum, ICD, CRT-D, launch, Europe and Japan

Image courtesy of LivaNova PLC


November 4, 2015 — LivaNova PLC, formerly Sorin Group, launched Platinum, a new range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).

Platinum offers superior longevity thanks to technology that ensures extremely low electrical intrinsic consumption. In standard functioning conditions, the service life is projected to last over 14 years for the single-chamber ICD model, over 13 years for the dual-chamber ICD model and over 10 years for CRT-D devices.

More than 60 percent of patients are under 70 years of age at the time of their first implant, and more than one-third will require at least one replacement due to battery depletion. Replacement procedures are associated with twice as many surgical re-interventions as compared to de-novo procedures due to increased rates of complications, such as infections. The mortality rate in patients with an infection reaches 16.9 percent at one year and 27.5 percent at three years.

The longevity of Platinum aims to limit the number of device replacements, minimizing the risks that are inherent in replacement surgeries. That longevity has been achieved without compromising the size of the device: Platinum’s size ranges from 31cc to 33cc, and the ErgoformM design of the can, with its rounded shape and smooth edges, was designed to facilitate the implant procedure and improve patient comfort.

Platinum devices also feature proven therapeutic functions such as the PARAD+ arrhythmia discrimination algorithm; SafeR, a pacing mode which preserves natural heart conduction; and SonR, a hemodynamic sensor which automatically optimizes CRT settings.

For more information: www.livanova.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

Jan. 12, 202 — Abbott and AtaCor Medical have announced a collaboration to advance a next-generation investigational ...

Home January 13, 2026
Home
News | Implantable Cardioverter Defibrillator (ICD)

Sept. 16, 2025 — Elutia Inc., a pioneer in drug-eluting biomatrix technologies, has published clinical and preclinical ...

Home September 19, 2025
Home
News | Implantable Cardioverter Defibrillator (ICD)

Sept. 2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter ...

Home September 05, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
Subscribe Now